TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12032266
Drug: Combination regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination regimen (colestipol 5 g/d with pravastatin 10 mg/d)
Study: 12032266
Drug: Conventional regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional regimen (colestipol 10 g/d)
Study: 9650540
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine therapy at 11 mg/day
Study: 9650540
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine therapy at 22 mg/day
Study: 9650540
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal nicotine therapy at 44 mg/day
Study: 2716711
Drug: Jatrox (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jatrox (three times 2 tablets one hour before meals)
Study: 29908682
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g Melissa officinalis (MO) supplement daily for 8 weeks
Study: 26855550
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia with 0.5 mg/mL morphine
Study: 22634446
Drug: 5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µg or 25 µg VLP immunotherapy
Study: 22634446
Drug: 1 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg VLP immunotherapy
Study: 22634446
Drug: Placebo immunotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo immunotherapy (0.9% NaCl)
Study: 15882248
Drug: Placebo during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo during H. pylori eradication and for 3 weeks following treatment.
Study: 26210512
Drug: Probiotic therapy
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic therapy
Study: 8834888
Drug: Rufloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin (400 mg, single dose)
Study: 19670810
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg twice a day for 3 days)
Study: 1557681
Drug: Family intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Family intervention combined with individual treatment
Study: 1557681
Drug: Individual treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual treatment alone
Study: 3891615
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (n = 10) with maintained urinary sodium excretion at predieting level
Study: 27050325
Drug: Prehabilitation (one-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prehabilitation (one-hour twice-weekly sessions for at least three and a maximum of four weeks prior to surgery)
Study: 19903661
Drug: Enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 20 mg o.d. and Candesartan 16 mg o.d. (combined treatment)
Study: 8738773
Drug: Lithium heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium heparin containers
Study: 1879192
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg b.i.d. for 7 consecutive days
Study: 1879192
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg b.i.d. for 3 consecutive days
Study: 7104133
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 10 ml
Study: 28359862
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg intravenous bolus)
Study: 21940091
Drug: Lidocaine with
Normalized name: Lidocaine with Tegaderm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine with epinephrine (12.5 μg/mL)
Study: 18602820
Drug: Isoflavone tablets
Normalized name: Soy isoflavones
DrugBank: Isoflavone (DB12007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone tablets at 144 mg/day
Study: 18602820
Drug: Isoflavone tablets
Normalized name: Soy isoflavones
DrugBank: Isoflavone (DB12007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavone tablets at 288 mg/day
Study: 18602820
Drug: Soy foods
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy foods providing 96 mg isoflavones/day
Study: 20619624
Drug: Ciclesonide (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclesonide (all doses)
Study: 1514166
Drug: Combined low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined low dose aspirin (75 mg) and low intensity anticoagulation (INR 1.5)
Study: 1514166
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin alone (A)
Study: 1514166
Drug: Double placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double placebo treatment (P)
Study: 1514166
Drug: Combined low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined low dose aspirin and low intensity anticoagulation (WA)
Study: 6504946
Drug: Hydroxychloroquine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (600 mg to 1400 mg)
Study: 18036981
Drug: Standard analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic care plus immersive VR distraction
Study: 18036981
Drug: Standard analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic care
Study: 15452689
Drug: Pamidronate (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (acute intravenous administration within 10 days of burn injury and again 1 week later)
Study: 9408071
Drug: Metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 850 mg b.i.d. (n = 10)
Study: 9408071
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg b.i.d. (n = 10)
Study: 8010581
Drug: Perioperative administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative administration of antibiotics
Study: 8010581
Drug: Prolonged perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged perioperative administration of antibiotics into the postoperative period
Study: 27441418
Drug: Featback with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Featback with low-intensity therapist support (weekly)
Study: 22902987
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg DAS infusion
Study: 22902987
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg DAS infusion
Study: 22902987
Drug: 320 mg
Normalized name: aspirin 320 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320 mg DAS infusion
Study: 22902987
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of DAS infusion
Study: 20406154
Drug: Walking to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking to school daily
Study: 12681875
Drug: Alendronate 35
Normalized name: ALENDRONATE 35MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 35 mg once weekly
Study: 10999794
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg daily
Study: 10872646
Drug: Amiodarone dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone dosing regimen of 1600 mg/d for 2 days, 1200 mg/d for 5 days, 1000 mg/d for 7 days, 800 mg/d for 7 days, 600 mg/d for 7 days, and 400 mg/d for 62 days followed by a maintenance dose of 343 mg/d (400 mg/d for 6 of 7 days)
Study: 2415098
Drug: Topical framycitin/gramicidin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical framycitin/gramicidin (Sofradex)
Study: 12030960
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg for 7 days)
Study: 9933263
Drug: High titers
Normalized name: Immune Globulin (Human) containing high titers of West Nile virus antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: High titers of antibodies to Chlamydia pneumoniae (IgA or IgG)
Study: 2276774
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (68 babies for prophylactic study, 34 babies for treatment study)
Study: 361348
Drug: Carbenoxolone/alginate antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone/alginate antacid combination
Study: 361348
Drug: Alginate antacid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate antacid compound used alone
Study: 31359143
Drug: TNFi treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFi treatment
Study: 31484710
Drug: ocrelizumab (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: ocrelizumab (600 mg)
Study: 21924882
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d EPA + DHA
Study: 18458964
Drug: Low-energy laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy laser (LEL) treatment as preventive treatment
Study: 18458964
Drug: Low-energy laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy laser (LEL) treatment as therapeutic intervention
Study: 11085323
Drug: MDMA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA treatment
Study: 6353434
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg prazepam (divided dosage)
Study: 6353434
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg prazepam (single night time dosage)
Study: 6353434
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg diazepam (divided dosage)
Study: 24714489
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO3) infusion
Study: 24714489
Drug: NAC in
Normalized name: diclofenac Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC in combination with NaHCO3
Study: 24714489
Drug: Hydration with
Normalized name: Gold Bond Healing Hydration with Aloe Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration with sodium chloride infusion alone
Study: 24714489
Drug: Sodium chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium chloride infusion alone
Study: 21182457
Drug: V-5 Immunitor
Normalized name: V-5 Immunitor
DrugBank: Tubimod (DB17745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: V-5 Immunitor (V5) immunotherapy pill
Study: 19018197
Drug: Ultrasonic mist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic mist therapy
Study: 19018197
Drug: Sham device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham device or alternative treatments
Study: 16763747
Drug: LKFibre diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LKFibre diet (17-30 g/day fiber)
Study: 14670885
Drug: Borage oil
Normalized name: Borage oil
DrugBank: Borage oil (DB11238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Borage oil (920 mg gamma linolenic acid) - adults received four capsules twice daily, children received two capsules twice daily for 12 weeks.
Study: 14670885
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - control group receiving placebo treatment for 12 weeks.
Study: 30012185
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of monomeric and oligomeric flavanols (MOF) daily for 3 months
Study: 20129679
Drug: Sodium diclofenac
Normalized name: Diclofenac Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium diclofenac 1mg/kg per-rectal post-induction of anaesthesia
Study: 14619641
Drug: Alendronate, 10
Normalized name: Alendronate, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate, 10 mg, daily for 6 months
Study: 1760826
Drug: Isosorbide-5-mononitrate (ISMN),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (ISMN), orally 20 mg 2-3 times daily
Study: 7051813
Drug: Oral erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral erythromycin therapy
Study: 24211154
Drug: Static progressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Static progressive stretch device plus traditional therapy
Study: 18756743
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy alone
Study: 12078788
Drug: Low-dose aprotinin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose aprotinin (2 x 10(6) KIU = 280 mg)
Study: 25740906
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract supplementation (0.56 g/d epigallocatechin gallate + 0.28-0.45 g/d caffeine)
Study: 22830987
Drug: Jet injection
Normalized name: Jet Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet injection of rapid-acting insulin analogs
Study: 31154419
Drug: Sequential co-enrolment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential co-enrolment in randomized trials
Study: 31066303
Drug: 0.35 mg
Normalized name: nicotine 0.35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.35 mg oral norethindrone with continuation of transdermal oestradiol patches (NET)
Study: 31066303
Drug: Oestradiol withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol withdrawal by patch removal (E2WD)
Study: 19230461
Drug: Phenylephrine 12
Normalized name: chlorcyclizine-phenylephrine 12.5 mg-5 mg/5 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 12 mg
Study: 3527811
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (MPSS), 2 to 3 g i.v. three hours apart within 12 hours of chest pain onset
Study: 27344822
Drug: Warm needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needling therapy and auricular acupuncture (observation group)
Study: 27344822
Drug: Warm needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm needling therapy (control group)
Study: 15676086
Drug: Control (normothermia,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (normothermia, no hypothermia treatment)
Study: 8714860
Drug: Standard zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard zinc therapy
Study: 27749534
Drug: Cabergoline 0.5
Normalized name: cabergoline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.5 mg, once per week for 3 months
Study: 8740091
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (T) of tamoxifen 30 mg
Study: 8740091
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (R) of N-desmethyl-tamoxifen
Study: 25149383
Drug: FGR group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGR group with treatment (animal experiment)
Study: 25149383
Drug: FGR group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FGR group without treatment (animal experiment)
Study: 22968413
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of four probiotics and four fibres
Study: 10853971
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg once daily
Study: 10853971
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg twice daily
Study: 24205802
Drug: Adductor canal
Normalized name: Canalevia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adductor canal blockade with 30 ml ropivacaine 7.5 mg/ml (n=36)
Study: 21416785
Drug: Adjustable dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable dosing of budesonide/formoterol (Symbicort, 80/4.5 microg and 160/4.5 microg)
Study: 15860863
Drug: Routine screening,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine screening, evaluation, and treatment
Study: 18727454
Drug: Thiocolchicoside 8
Normalized name: Etoricoxib 90 mg and thiocolchicoside 8 mg conventional release and prolonged-release oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiocolchicoside 8 mg twice daily (b.i.d.)
Study: 15779223
Drug: Intraosseous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous injection using 2% lidocaine with 1:100,000 epinephrine
Study: 15779223
Drug: Infiltration injection
Normalized name: LIDOCAINE HYDROCHLORIDE 0.02 g in 1 mL INFILTRATION INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration injection using 2% lidocaine with 1:100,000 epinephrine
Study: 8646872
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 0.005% ointment, applied topically up to 100 gm/week, twice daily for up to four weeks
Study: 6390802
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (Solu-Medrol) in addition to antibiotics and early surgical intervention
Study: 25113885
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine (2 mg/kg) and glucosamine (25 mg/kg) for 8 weeks
Study: 25113885
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine alone for 8 weeks
Study: 12888783
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose ketamine
Study: 12888783
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose ketamine
Study: 2296626
Drug: Caffeine 250
Normalized name: caffeine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 250 mg
Study: 1444724
Drug: Caffeine 500
Normalized name: aspirin-caffeine 500 mg-32 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 500 mg
Study: 12648865
Drug: HRT (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (a combination of oral conjugated estrogen 0.625 mg and medroxyprogesterone acetate 5 mg daily)
Study: 12648865
Drug: HRT +
Normalized name: Hormone Replacement Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT + MFP (HRT combined with oral monofluorophosphate 25 mg per day)
Study: 12648865
Drug: MFP (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MFP (oral monofluorophosphate 25 mg per day)
Study: 8985298
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg daily
Study: 8752839
Drug: Topical phosphodiesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical phosphodiesterase inhibitor (CP80,633)
Study: 1872724
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of sublingual nifedipine
Study: 11295959
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil hydrochloride (240 mg/d)
Study: 1826912
Drug: Nifedipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (30 mg/d)
Study: 3552106
Drug: Gentamicin 80
Normalized name: gentamicin 80 mg/50 mL-0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 80 mg IV
Study: 30507887
Drug: Osteotome site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteotome site preparation (Control)
Study: 12139210
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (2 g metamizole)
Study: 10460199
Drug: Diurnal oral
Normalized name: Diuresal Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diurnal oral fat load test (OFLT) at 0700 h
Study: 2215101
Drug: 1.8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 mg/kg propofol
Study: 2215101
Drug: 2.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg/kg propofol
Study: 25881872
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of piperacillin/tazobactam (11.25g/day on Day 1 followed by 9g/day)
Study: 25881872
Drug: Intermittent bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent bolus (IB) administration of piperacillin/tazobactam (11.25g/day on Day 1 followed by 9g/day)
Study: 25881872
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of piperacillin
Study: 17719703
Drug: Immediate oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate oral feeding
Study: 15113366
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy with rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. (low-dose therapy)
Study: 15113366
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy with rabeprazole 20 mg b.d. plus amoxicillin 1 g b.d. for the first 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 500 mg b.d. (high-dose therapy)
Study: 1748229
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (150 mg/day)
Study: 20649626
Drug: Fenofibrate (145
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate (145 mg/day)
Study: 11677198
Drug: Ethinylestradiol (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol (0.01 mg) plus norethisterone (2 mg) (1 tablet/d)
Study: 11677198
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 tablet/d)
Study: 9126796
Drug: Diuretics (spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (spironolactone 100-400 mg/day and furosemide 80-320 mg/day)